AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1352828 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 40
Study 6371693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (max dose, 350 mcg/min intravenously for 12 hours, then 20 mg orally every 4 hours)
Number of subjects: 35
Study 6371693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously for 12 hours, then oral therapy)
Number of subjects: 35
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Online teaching with typical pictures and APLOC definitions (Group A)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Definitions only (Group B)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Experts
Number of subjects: 248
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (ulceration)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Group B (ulceration)
Number of subjects: 248
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (fistulae)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Group B (fistulae)
Number of subjects: 248
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (erythema)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Group B (erythema)
Number of subjects: 248
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (anoperineal scars)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Group B (anoperineal scars)
Number of subjects: 248
Study 30935906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (abscess)
Number of subjects: 248
Study 30935906 — intervention group
Group type: COMPARATOR
Intervention: Group B (abscess)
Number of subjects: 248
Study 30021759 — intervention group
Group type: EXPERIMENTAL
Intervention: High phosphate diet (regular diet plus 1 mmol/kg body wt per day of Na as neutral sodium phosphate)
Number of subjects: 20
Study 30021759 — intervention group
Group type: EXPERIMENTAL
Intervention: High phosphate diet
Number of subjects: 20
Study 30021759 — intervention group
Group type: COMPARATOR
Intervention: Low phosphate diet (regular diet plus lanthanum, 750 mg thrice/day, plus 0.7 mmol/kg body wt per day of Na as NaCl)
Number of subjects: 20
Study 27320828 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 76
Study 27320828 — intervention group
Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 76
Study 24577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by lay providers (BLP), n = 76
Number of subjects: 223
Study 24577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP), n = 74
Number of subjects: 223
Study 24577847 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), n = 73
Number of subjects: 223
Study 24577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by lay providers (BLP)
Number of subjects: 223
Study 24577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP)
Number of subjects: 223
Study 22943664 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy using a pipelle curette on days 9‐12 and 21‐24 of the menstrual cycle preceding IVF treatment
Number of subjects: 36
Study 22943664 — intervention group
Group type: COMPARATOR
Intervention: Cervical pipelle performed (Control)
Number of subjects: 36
Study 19322797 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81
Study 19322797 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81
Study 17405883 — intervention group
Group type: EXPERIMENTAL
Intervention: Afferent stimulation combined with task-specific training
Number of subjects: 20
Study 17405883 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 20
Study 15056575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy for command hallucinations (CTCH)
Number of subjects: 38
Study 15056575 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 38
Study 11466749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted secondary prevention intervention including training sessions for caregivers, information sessions for personnel, residents, and relatives, and group interventions.
Number of subjects: 213
Study 11466749 — intervention group
Group type: EXPERIMENTAL
Intervention: High GDS scoring participants from the intervention group.
Number of subjects: 213
Study 11466749 — intervention group
Group type: COMPARATOR
Intervention: Control group (211 residents from matched residential homes).
Number of subjects: 213
Study 9683362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g six times a day during radiotherapy)
Number of subjects: 102
Study 9683362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9683362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 102
Study 7530379 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg dose in caplet form)
Number of subjects: 24
Study 7530379 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg dose in tablet form)
Number of subjects: 24
Study 3346865 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 20
Study 3346865 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1500 mg
Number of subjects: 20
Study 28595236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33
Study 28595236 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study 27649258 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoblock polyethylene insert
Number of subjects: 53
Study 27649258 — intervention group
Group type: COMPARATOR
Intervention: Modular polyethylene insert
Number of subjects: 53
Study 25217488 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity ratio (VR) <0.25
Number of subjects: 435
Study 25217488 — intervention group
Group type: COMPARATOR
Intervention: Velocity ratio (VR) >0.25
Number of subjects: 435
Study 25217488 — intervention group
Group type: COMPARATOR
Intervention: Mean pressure gradient (MPG)
Number of subjects: 435
Study 25217488 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity ratio (VR)
Number of subjects: 435
Study 25217488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted aortic valve area (AVA) by VR
Number of subjects: 435
Study 22819386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated medication reconciliation
Number of subjects: 218
Study 22819386 — intervention group
Group type: COMPARATOR
Intervention: Physician-initiated medication reconciliation
Number of subjects: 218
Study 20715595 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of algal DHA
Number of subjects: 1094
Study 20715595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study 18846487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-sacrificing NexGen Full Flex implant
Number of subjects: 44
Study 18846487 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-retaining CKS-CC knee system
Number of subjects: 44
Study 16838494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zwislocki-type adaptive procedure
Number of subjects: 0
Study 16838494 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitt-type adaptive procedure
Number of subjects: 0
Study 16838494 — intervention group
Group type: COMPARATOR
Intervention: Both adaptive procedures
Number of subjects: 0
Study 12813340 — intervention group
Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks
Number of subjects: 50
Study 12813340 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon immobilization in tension using a below‐knee cast with the ankle in a neutral position for 6 weeks
Number of subjects: 50
Study 10590505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control and anticoagulation
Number of subjects: 3000
Study 10590505 — intervention group
Group type: COMPARATOR
Intervention: Rate control and anticoagulation
Number of subjects: 3000
Study 9012115 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine (100 micrograms iodide)
Number of subjects: 88
Study 9012115 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (50 micrograms selenium)
Number of subjects: 88
Study 9012115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iodine and selenium
Number of subjects: 88
Study 9012115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 88
Study 1636917 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 1636917 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study 6712366 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted (CA) initial lidocaine hydrochloride therapy
Number of subjects: 156
Study 6712366 — intervention group
Group type: COMPARATOR
Intervention: Conventional lidocaine therapy (CT)
Number of subjects: 156
Study 30879006 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 260
Study 30879006 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 260
Study 29884676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tryptophan
Number of subjects: 641
Study 29884676 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive changes in quinolinic acid from baseline to 1 year
Number of subjects: 641
Study 29884676 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tryptophan and kynurenic acid
Number of subjects: 641
Study 29884676 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent changes in kynurenine, quinolinic acid, 3‐hydroxyanthranilic acid, and kynurenine/tryptophan ratio
Number of subjects: 641
Study 26341357 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Treatment (EBT)
Number of subjects: 79
Study 26341357 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 79
Study 24732629 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma vitamin D (25-hydroxy) concentration
Number of subjects: 1731
Study 24732629 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vitamin D levels
Number of subjects: 1731
Study 22865603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrates Diet
Number of subjects: 305
Study 22865603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Number of subjects: 305
Study 20378050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active plant metabolites (e.g., flavonoids, terpenoids, glycosides) as digestive enzyme inhibitors; specific dosage and duration not available.
Number of subjects: 0
Study 20378050 — intervention group
Group type: COMPARATOR
Intervention: Currently used digestive enzyme inhibitors (bacterial secondary metabolites); specific dosage and duration not available.
Number of subjects: 0
Study 18049291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stacking multiple intervention components (child-based program, parent training program, teacher-based program)
Number of subjects: 459
Study 18049291 — intervention group
Group type: COMPARATOR
Intervention: Single intervention components (child-based program, parent training program, teacher-based program)
Number of subjects: 459
Study 16754441 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme®
Number of subjects: 0
Study 16754441 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 16754441 — intervention group
Group type: COMPARATOR
Intervention: Blood
Number of subjects: 0
Study 14602215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepid blood cardioplegia (CP)
Number of subjects: 100
Study 14602215 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (CP)
Number of subjects: 100
Study 14602215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10912657 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 40
Study 10912657 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 8803529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (600 mg)
Number of subjects: 7
Study 8803529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1538234 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning for TIA
Number of subjects: 2082
Study 1538234 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning for RIND
Number of subjects: 2082
Study 1538234 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning for minor stroke
Number of subjects: 2082
Study 6704005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 100 spots over 360 degrees
Number of subjects: 45
Study 6704005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 50 spots over 180 degrees
Number of subjects: 45
Study 6704005 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 50 spots over 360 degrees
Number of subjects: 45
Study 30790160 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 30790160 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 27998700 — intervention group
Group type: EXPERIMENTAL
Intervention: Section 8 voucher to move to lower poverty neighborhoods
Number of subjects: 2829
Study 27998700 — intervention group
Group type: COMPARATOR
Intervention: Control group (public housing)
Number of subjects: 2829
Study 25083614 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rabbit antithymocyte globulin (SD-rATG) 6 mg/kg
Number of subjects: 180
Study 25083614 — intervention group
Group type: COMPARATOR
Intervention: Divided-dose rabbit antithymocyte globulin (divided-dose-rATG)
Number of subjects: 180
Study 25083614 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-rATG
Number of subjects: 180
Study 25083614 — intervention group
Group type: COMPARATOR
Intervention: SD-rATG and divided-dose-rATG
Number of subjects: 180
Study 23188543 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 90
Study 23188543 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study 21540604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube group (TG)
Number of subjects: 161
Study 21540604 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative tube group (ITG)
Number of subjects: 161
Study 21540604 — intervention group
Group type: COMPARATOR
Intervention: No-tube group (NTG)
Number of subjects: 161
Study 18310205 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm, weaned to 2 ppm)
Number of subjects: 100
Study 18310205 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 100
Study 17077928 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective head cooling with an insulated ice cap, aiming for a target rectal temperature of 35-35.5 degrees C and a target scalp temperature of 10-28 degrees C.
Number of subjects: 20
Study 17077928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling technique using an insulated ice cap with additional insulation.
Number of subjects: 20
Study 17077928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling technique with lower core temperatures of 33-34 degrees C.
Number of subjects: 20
Study 15226338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult oncology informed consent process
Number of subjects: 219
Study 15226338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric oncology informed consent process
Number of subjects: 219
Study 10694138 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus caffeine (Pr+C)
Number of subjects: 15
Study 10694138 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (Pr)
Number of subjects: 15
Study 10694138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 15
Study 9186381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg/day) started within 48 hours of onset of suspected acute ischaemic stroke and continued for up to 4 weeks
Number of subjects: 21106
Study 9186381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg/day)
Number of subjects: 21106
Study 9186381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21106
Study 1402726 — intervention group
Group type: EXPERIMENTAL
Intervention: CPCP office system intervention
Number of subjects: 50
Study 3880687 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice a day)
Number of subjects: 7
Study 3880687 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 7
Study 3880687 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg twice a day)
Number of subjects: 7
Study 3880687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice a day)
Number of subjects: 7
Study 3880687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30209858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-drinking
Number of subjects: 466434
Study 30209858 — intervention group
Group type: COMPARATOR
Intervention: Genetically assessed unit of alcohol/week
Number of subjects: 466434
Study 29982097 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise (25 repetitions, 3 times daily)
Number of subjects: 120
Study 29982097 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise (25 repetitions, 6 times daily)
Number of subjects: 120
Study 29982097 — intervention group
Group type: COMPARATOR
Intervention: Control group (gentle limb exercise with no frequency and intensity requirements)
Number of subjects: 120
Study 29982097 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27509600 — intervention group
Group type: COMPARATOR
Intervention: Control group (acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine)
Number of subjects: 68
Study 24532830 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 90
Study 24532830 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 90
Study 24532830 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttrial colchicine use
Number of subjects: 90
Study 23082123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment (75 mg twice a day for 5 days)
Number of subjects: 652
Study 23082123 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir treatment and prophylaxis (75 mg once a day for 10 days)
Number of subjects: 652
Study 20111881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal swab
Number of subjects: 98
Study 20111881 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal aspirate
Number of subjects: 98
Study 20111881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal swab in children with severe symptoms
Number of subjects: 98
Study 20111881 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection
Number of subjects: 98
Study 17623227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0:10 sucrose:lactitol
Number of subjects: 75
Study 17623227 — intervention group
Group type: COMPARATOR
Intervention: 10:0 sucrose:lactitol
Number of subjects: 75
Study 17623227 — intervention group
Group type: COMPARATOR
Intervention: 5:5 sucrose:lactitol
Number of subjects: 75
Study 15705721 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based approach for quantifying central activation failure (CAF) during a 2-min sustained maximal voluntary contraction (MVC).
Number of subjects: 27
Study 15705721 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based approach for quantifying peripheral fatigue (PF) during sustained MVC.
Number of subjects: 27
Study 15705721 — intervention group
Group type: COMPARATOR
Intervention: Linear interpolation method for estimating peripheral fatigue (PF).
Number of subjects: 27
Study 12204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment methodology
Number of subjects: 1026
Study 12204663 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for future investigations
Number of subjects: 1026
Study 9449256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (2 g twice daily)
Number of subjects: 400
Study 9449256 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g three times daily)
Number of subjects: 400
Study 7616306 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein ingestion
Number of subjects: 4
Study 7616306 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean protein ingestion
Number of subjects: 4
Study 7616306 — intervention group
Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 4
Study 2792903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone plus sulbactam (antimicrobial prophylaxis)
Number of subjects: 21
Study 2792903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 367853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 10
Study 367853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30017177 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL‐apoA‐I exchange (HAE)
Number of subjects: 93
Study 28879896 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 28879896 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 25644856 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (4 g day(-1) for 4 weeks)
Number of subjects: 24
Study 24129009 — intervention group
Group type: EXPERIMENTAL
Intervention: Deductive teaching procedure
Number of subjects: 66
Study 24129009 — intervention group
Group type: COMPARATOR
Intervention: Inductive teaching procedure
Number of subjects: 66
Study 22902097 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector prefilled pen (PFP)
Number of subjects: 0
Study 22902097 — intervention group
Group type: COMPARATOR
Intervention: Prefilled syringe (PFS)
Number of subjects: 0
Study 22902097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (PFP and PFS)
Number of subjects: 0